Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Randomized, International, Open-Label Phase III Study to Assess the Effect of a Patient Outreach Program on the Percentage of Time Patients With Locally Advanced or Metastatic Medullary Thyroid Cancer (MTC) Experience Grade 2 or Higher AEs in the First 12 Months of Treatment With Vandetanib

Next Previous
Trial Profile

A Randomized, International, Open-Label Phase III Study to Assess the Effect of a Patient Outreach Program on the Percentage of Time Patients With Locally Advanced or Metastatic Medullary Thyroid Cancer (MTC) Experience Grade 2 or Higher AEs in the First 12 Months of Treatment With Vandetanib

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 28 Apr 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Vandetanib (Primary)
  • Indications Thyroid cancer
  • Focus Adverse reactions; Registrational
  • Acronyms 88
  • Sponsors AstraZeneca; AstraZeneca AB; Sanofi Genzyme

Most Recent Events

  • 24 Apr 2025 Status changed from active, no longer recruiting to completed.
  • 10 Feb 2025 Planned End Date changed from 29 Nov 2024 to 31 Jan 2025.
  • 04 Dec 2024 Planned End Date changed from 28 Jun 2024 to 29 Nov 2024.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top